Evidence map›Paper›PMID 29325138›Full record

ArticleThe Journal of infectious diseases2018

Evidence for Viral Interference and Cross-reactive Protective Immunity Between Influenza B Virus Lineages.

Karen L Laurie, William Horman, Louise A Carolan, Kok Fei Chan, Daniel Layton, Andrew Bean, Dhanasekaran Vijaykrishna, Patrick C Reading, James M McCaw, Ian G Barr

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Risk factors for severe lower respiratory tract infection among children under 5 years of age hospitalized with respiratory syncytial virus.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Observational
  5. Influenza Vaccine Effectiveness in Australia During 2017-2019.Influenza and other respiratory viruses · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. [The Victoria and Yamagata Lineages of Influenza B Viruses, unknown and undervalued].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Review
  19. Viral Interference between Respiratory Viruses.Emerging infectious diseases · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Karen L LaurieWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia.
William HormanDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia.
Louise A CarolanWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia.
Kok Fei ChanWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia.
Daniel LaytonAustralian Animal Health Laboratory, Health and Biosecurity Unit, Commonwealth Scientific and Industrial Research Organisation, Geelong, Australia.
Andrew BeanAustralian Animal Health Laboratory, Health and Biosecurity Unit, Commonwealth Scientific and Industrial Research Organisation, Geelong, Australia.
Dhanasekaran VijaykrishnaDepartment of Microbiology, School of Biomedical Sciences, Monash University, Clayton, Australia.
Patrick C ReadingWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia.
James M McCawCentre for Epidemiology and Biostatistics, School of Mathematics and Statistics and Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.
Ian G BarrWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia.
Victorian Infectious Diseases Reference Laboratory · AUCommonwealth Scientific and Industrial Research Organisation · AUAustralian Regenerative Medicine Institute · AUFederation University · AUMurdoch Children's Research Institute · AUPeter Doherty Institute · AUUniversity of Melbourne · AU

Funding

NIAID NIH HHS HHSN272201400006C
6 · The paper itself

Abstract

Background: Two influenza B virus lineages, B/Victoria and B/Yamagata, cocirculate in the human population. While the lineages are serologically distinct, cross-reactive responses to both lineages have been detected. Viral interference describes the situation whereby infection with one virus limits infection and replication of a second virus. We investigated the potential for viral interference between the influenza B virus lineages. Methods: Ferrets were infected and then challenged 3, 10, or 28 days later with pairs of influenza B/Victoria and B/Yamagata viruses. Results: Viral interference occurred at challenge intervals of 3 and 10 days and occasionally at 28 days. At the longer interval, shedding of challenge virus was reduced, and this correlated with cross-reactive interferon γ responses from lymph nodes from virus-infected animals. Viruses from both lineages could prevent or significantly limit subsequent infection with a virus from the other lineage. Coinfections were rare, indicating the potential for reassortment between lineages is limited. Conclusions: These data suggest that innate and cross-reactive immunity mediate viral interference and that this may contribute to the dominance of a specific influenza B virus lineage in any given influenza season. Furthermore, infection with one influenza B virus lineage may be beneficial in protecting against subsequent infection with either influenza B virus lineage.

Indexed as

Cross ProtectionViral InterferenceAnimalsCross ReactionsDisease Models, AnimalFerretsImmunity, InnateInfluenza B virusOrthomyxoviridae Infectionscross-protectiondominanceferretinfluenzainfluenza BlineageViral interference

Identifiers

PMID29325138
PMCPMC5853430
OpenAlexW2782383464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.